What is Rapid Micro Biosystems?
Rapid Micro Biosystems provides mission-critical automation solutions designed to enhance the efficiency and safety of healthcare product manufacturing. Its flagship Growth Direct System automates and modernizes traditional, manual microbial quality control (MQC) testing workflows. This system is deployed in large-scale pharmaceutical manufacturing operations globally, bringing MQC testing directly to the manufacturing floor. The automation aims to deliver faster results, improved accuracy, increased operational efficiency, enhanced compliance with data integrity regulations, and quicker decision-making, all crucial for ensuring the safe and consistent supply of vital healthcare products. The company is headquartered in Lowell, Massachusetts, with additional global operations.
How much funding has Rapid Micro Biosystems raised?
Rapid Micro Biosystems has raised a total of $396.7M across 10 funding rounds:
Series B
$32.6M
Private Equity
$6M
Debt
$6M
Series C
$25M
Other Financing Round
$60M
Other Financing Round
$120M
Other Financing Round
$81M
Debt
$45M
Series B (2013): $32.6M supported by Kleiner Perkins Caufield & Byers, Quaker Partners, TVM Capital, TPG Biotech, and Longitude Capital
Private Equity (2014): $6M featuring TPG Biotech, Longitude Capital, Kleiner Perkins Caufield & Byers, Quaker Partners, and TVM Capital
Debt (2015): $6M, investors not publicly disclosed
Series C (2015): $25M with participation from TPG Biotech, Hepalink, Longitude Capital, Kleiner Perkins Caufield & Byers, Richard K. Mellon and Sons, Quaker Partners, and TVM Capital
Other Financing Round (2018): $60M led by Bain Capital and Xeraya Capital
Other Financing Round (2020): $120M supported by Xeraya Capital, Bain Capital, Asahi Kasei Medical, Ally Bridge Group, Longitude Capital, and Endeavour Vision
Other Financing Round (2021): $81M featuring Asahi Kasei Corporation, Xeraya Capital, T. Rowe Price, Sunley House Capital Management, BlackRock, Caas Capital Management, Adage Capital Management, Bain Capital, Ally Bridge Group, D1 Capital Partners, Quaker BioVentures, Longitude Capital, and Endeavour Vision
Debt (2025): $45M backed by Trinity Capital
Key Investors in Rapid Micro Biosystems
Bain Capital
Bain Capital is a global investment firm known for its private equity, growth, and venture capital strategies. They focus on creating lasting impact by supporting portfolio companies with operational and strategic expertise across various industries, including life sciences.
Kleiner Perkins Caufield & Byers
Kleiner Perkins is a prominent venture capital firm that invests in early and growth-stage technology and life science companies. They provide capital and operational support to help founders scale their innovative ventures from seed stage through IPO or acquisition.
Longitude Capital
Longitude Capital is a venture capital firm dedicated to investing in the healthcare sector, including biotechnology, medical technology, and health solutions. They leverage sector expertise and active partnership to help innovators scale and improve patient care.
What's next for Rapid Micro Biosystems?
The substantial capital raised by Rapid Micro Biosystems, particularly the recent strategic investment, positions the company for accelerated growth and further innovation in the life sciences automation sector. This funding is expected to fuel the expansion of its Growth Direct System's capabilities and market reach, addressing the increasing demand for advanced quality control solutions in pharmaceutical and biopharmaceutical manufacturing. The company's focus on critical healthcare products suggests a trajectory towards becoming a dominant player in ensuring product safety and regulatory compliance within a rapidly evolving industry.
See full Rapid Micro Biosystems company page
